



6th International Conference on Nanotechnologies and Biomedical Engineering  
Proceedings of ICNBME-2023, September 20–23, 2023, Chisinau, Moldova  
Volume 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and Rehabilitation

## ***In vivo* and *in silico* Studies of the Neuroprotective Effect of Artemisinin in Prevention of Alzheimer’s Disease in an Animal Model**

**Susanna Tiratsuyan, Yelena Hambardzumyan, Michael Poghosyan, Margarita Danielyan, Ashkhen Hovhannisyan**

[https://doi.org/10.1007/978-3-031-42782-4\\_22](https://doi.org/10.1007/978-3-031-42782-4_22)

### **Abstract**

Currently, artemisinin (ART) and many of its semisynthetic derivatives are considered as potential neuroprotectors. The effect of ART in an animal model of Alzheimer’s disease (AD) induced by aggregated amyloidogenic peptide  $A\beta_{1-42}$  was studied by electrophysiology and morphology analysis to detect changes in brain memory caused by activation of the entorhinal cortex as synaptic potentiation and depression as well as identifying a correlation with *in silico* studies of the direct interaction of ART with amyloidogenic peptides  $5A\beta_{17-42}$  and  $18A\beta_{9-40}$ .

We have shown the preventive effect of ART in an animal model of AD. Electrophysiological studies showed that in the pre-injection of ART, there is an obvious and significant decrease in excitotoxicity, which precedes both depressor and excitatory post-stimulus effects, approaching normal, indicating its powerful protective effect. Protection was more effective in relation to the depressor sequence. Histo-morphological analysis showed that the preliminary injection of ART acts as a neuroprotective agent that prevents or slows down damage to brain tissue and also promotes the restoration of neurons and their environment.

The conducted *in silico* studies indicate the direct interaction of ART with amyloidogenic peptides  $5A\beta_{17-42}$  and  $18A\beta_{9-40}$  with high binding energies. At the same



**6th International Conference on Nanotechnologies and Biomedical Engineering  
Proceedings of ICNBME-2023, September 20–23, 2023, Chisinau, Moldova  
Volume 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and  
Rehabilitation**

time, ART can stop the formation and growth of the 18A $\beta$ 9–40 fibril, as well as destabilize the already formed amyloid, which correlates with in vivo studies.

*Keywords: Alzheimer’s disease, amyloidogenic peptides, peptides, memory*

## References

1. Hill, S.R., Thakur, R.K., Sharma, G.K.: Antimalarial Medications. StatPearls. Treasure Island (FL). StatPearls Publishing (2023). <https://www.ncbi.nlm.nih.gov/books/NBK470158/>
2. Krishna, S., Bustamante, R.K., Haynes, H.M.: Staines ARTs: their growing importance in medicine. Trends Pharmacol. Sci. **29**(10), 520–527 (2008)
3. Lisgarten, J., Potter, B., Palmer, R., James, E.: Pitts: structure, absolute configuration, and conformation of the antimalarial compound. ART J. Chem. Crystallogr. **128**(7), 539–543 (1998)
4. O’Neill, P.M., Barton, V., Ward, S.: The molecular mechanism of action of ART – the debate continues. Molecules **15**(3), 1705–1721 (2010)
5. Raffetin, A., Bruneel, F., Roussel, C.: Use of artesunate in non-malarial indications. Med. Mal. Infect. **48**, 238–249 (2018)
6. Das, A.: Anticancer effect of antimalarial ART compounds. Ann. Med. Health Sci. Res. **5**(2), 93 (2015)
7. Wong, Y.K., et al.: Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med. Res. Rev. **37**(6), 1492–1517 (2017)
8. Crespo-Ortiz, M.P., Wei, M.Q.: Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J. Biomed Biotechnol. 247597 (2012). <https://doi.org/10.1155/2012/247597>
9. Huang, M., et al.: Preliminary study on antibacterial activity of artemisinin and its derivatives// Zhongguo Zhong yao za zhi=Zhongguo zhongyao zazhi=China J. Chin. Mater. Med. **44**(9), 1946–1952 (2019)
10. Ginosyan, S., Grabski, H., Tiratsuyan, S.: Mol. Biol. **54**(4), 653–666 (2020)



**6th International Conference on Nanotechnologies and Biomedical Engineering  
Proceedings of ICNBME-2023, September 20–23, 2023, Chisinau, Moldova  
Volume 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and  
Rehabilitation**

11. Appalasamy, S., Lo, K. Y., Ch'ng, S. J., Nornadia, K., Othman, A. S., Chan, L. K.: Antimicrobial activity of artemisinin and precursor derived from in vitro plantlets of *Artemisia annua* L. *BioMed Res. Int.* 215872 (2014)
12. Nagshetty, K., Channappa, S. T., Gaddad, S. M.: Antimicrobial susceptibility of *Salmonella typhi* in India. *J. Infect. Dev. Ctries.* **4**(2), 70–73 (2010)
13. Li, B., et al.: Antimalarial artesunate protects sepsis model mice against heat-killed *Escherichia coli* challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. *Int. Immunopharmacol.* **8**(3), 379–389 (2008)
14. Shi, Z., Chen, Y., Lu, C., et al.: Resolving neuroinflammation, the therapeutic potential of the anti-malaria drug family of ART. *Pharmacol. Res.* **136**, 172–180 (2018)
15. Innamorato, N., Lastres-Becker, I., Cuadrado, A.: Role of microglial redox balance in modulation of neuroinflammation. *Curr. Opin. Neurol.* **22**(3), 308–314 (2009).  
<https://doi.org/10.1097/WCO.0b013e32832a3225>
16. Okorji, U. P., Velagapudi, R., El-Bakoush, A., Fiebich, B. L., Olajide, O. A.: Antimalarial drug artemether inhibits neuroinflammation in BV2 microglia through Nrf2-dependent mechanisms. *Mol. Neurobiol.* **53**(9), 6426–6443 (2016)
17. Yao, W., Wang, F., Wang, H.: Immunomodulation of ART and its derivatives. *Sci. Bull.* **61**, 1399–1406 (2016). <https://doi.org/10.1007/s11434-016-1105-z>
18. Ying, M., Liu, H., Zhang, T., et al.: Effect of ART on neuropathic pain mediated by P2X4 receptor in dorsal root ganglia. *Neurochem. Int.* **108**, 27–33 (2017)
19. Xu, G., Huang, Y. L., Li, P. L.: Neuroprotective effects of ART against isoflurane-induced cognitive impairments and neuronal cell death involve JNK/ERK1/2 signalling and improved hippocampal histone acetylation in neonatal rats. *J. Pharm. Pharmacol.* **69**, 684–697 (2017). <https://doi.org/10.1111/jphp.12704>
20. Lu, B. W., Baum, L., So, K. F., Chiu, K., Xie, L. K.: More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration. *Neural Regen. Res.* **14**(9), 1494–1498 (2019).  
<https://doi.org/10.4103/1673-5374.255960>
21. Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., Liddell, J. R.: Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. *Front. Neurosci.* **12**, 466 (2018)



**6th International Conference on Nanotechnologies and Biomedical Engineering  
Proceedings of ICNBME-2023, September 20–23, 2023, Chisinau, Moldova  
Volume 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and  
Rehabilitation**

22. Zheng, W., et al.: Artemisinin conferred ERK mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult. *Free Radic. Biol. Med.* **97**, 158–167 (2016)
23. Li, J., et al.: Artemisinins target GABAA receptor signaling and impair  $\alpha$  cell identity. *Cell* **168**(1–2), 86–100 (2017)
24. Wang, D., Wu, M., Li, S., Gao, Q., Zeng, Q.: Artemisinin mimics calorie restriction to extend yeast lifespan via a dual-phase mode: a conclusion drawn from global transcriptome profiling. *Sci. China Life Sci.* **58**(5), 451–465 (2015)
25. Groeneweg, F.L., Trattnig, C., Kuhse, J., et al.: Gephyrin: a key regulatory protein of inhibitory synapses and beyond. *Histochem. Cell Biol.* **150**, 489–508 (2018). <https://doi.org/10.1007/s00418-018-1725-2>
26. Kiss, E., et al.: Artemisinin-treatment in pre-symptomatic APP-PS1 mice increases gephyrin phosphorylation at Ser270: a modification regulating postsynaptic GABAAR density. *Biol. Chem.* **403**(1), 73–87 (2021)
27. Qiang, W., et al.: ART B improves learning and memory impairment in AD dementia mice by suppressing neuroinflammation. *Neuroscience* **395**, 1–12 (2018)
28. Zhao, X., Li, S., Gaur, U., Zheng, W.: ART improved neuronal functions in Alzheimer's disease animal model 3xtg mice and neuronal cells via stimulating the ERK/CREB signaling pathway. *Aging Dis.* **11**(4), 801–819 (2020)
29. Kasaragod, V.B., Hausrat, T.J., Schaefer, N.: Elucidating the molecular basis for inhibitory neurotransmission regulation by ARTs. *Neuron* **101**, 673–689 (2019)
30. Kwakowsky, A., Calvo-Flores Guzmán, B., Govindpani, K., Waldvogel, H.J., Faull, R.L.: Gamma-aminobutyric acid A receptors in Alzheimer's disease: highly localized remodeling of a complex and diverse signaling pathway. *Neural Regen. Res.* **13**(8), 1362–1363 (2018). <https://doi.org/10.4103/1673-5374.235240>
31. Vico Varela, E., Etter, G., Williams, S.: Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. *Neurobiol. Dis.* **127**, 605–615 (2019)



**6th International Conference on Nanotechnologies and Biomedical Engineering  
Proceedings of ICNBME-2023, September 20–23, 2023, Chisinau, Moldova  
Volume 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and  
Rehabilitation**

32. Shi, J.Q., Zhang, C.C., Sun, X.L., et al.: Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APP<sup>sw</sup>/PS1<sup>de9</sup> transgenic mice via inhibition of nuclear factor- $\kappa$ B and NLRP3 inflammasome activation. *CNS Neurosci. Ther.* **19**(4), 262–268 (2013). <https://doi.org/10.1111/cns.12066>
33. Paxinos, G., Watson, C.: *The Rat Brain in Stereotaxic Coordinates*, 5th edn. Elsevier, Academic Press (2005)
34. Palkovits, M.: *Maps and Guide to Microdissection of the Rat Brain*. Elsevier, New York, Amsterdam, London (1988)
35. Melikcet\_n, IB: By\_vlenie aktivnocti Ca<sup>2+</sup>-zavicimo\_ kiclo\_ focfatazy v kletqnyx ctpyktypax mozga kpyc. *Mopfologi\_* **131**(2), 77–80 (2007)
36. Trott, O., Olson, A.J.: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **31**, 455–461 (2010)
37. Laskowski, R.A., Swindells, M.B.: LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J. Chem. Inf. Model.* **51**, 2778–2786 (2011). <https://doi.org/10.1021/ci200227u>
38. DeLano, W.L.: Pymol: an open-source molecular graphics tool. *CCP4 Newsl. Protein Crystallogr.* **40**, 82–92 (2002)